Guggenheim Sees Biogen (BIIB) Down 15-20% After 'Worst Fears Come True'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
Go back to Guggenheim Sees Biogen (BIIB) Down 15-20% After 'Worst Fears Come True'
March 25, 2019 7:49 AM EDT
H.C. Wainwright analyst Andrew Fein lowered the price target on Biogen (NASDAQ: BIIB) to $300.00 (from $363.00) while maintaining a Buy rating following the discontinuation of Aducanumab. Despite limited details around the data, Fein thinks this development nevertheless points to the insufficiency in the current... More
March 21, 2019 10:06 AM EDT
Mizuho Securities analyst Salim Syed downgraded Biogen (NASDAQ: BIIB) from Buy to Neutral with a price target of $235.00.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $320.59 yesterday.
...
More
March 21, 2019 9:20 AM EDT
Cowen analyst Phil Nadeau lowered the price target on Biogen (NASDAQ: BIIB) to $275.00 (from $400.00) while maintaining a Outperform rating after the company announced that the Ph. III ENGAGE and EMERGE studies of aducanumab for the treatment of cognitive impairment and dementia in Alzheimer's... More
March 21, 2019 8:28 AM EDT
Citi analyst Robyn Karnauskas said Biogen (NASDAQ: BIIB) fair value is $241/share without AD
...
More
March 21, 2019 8:20 AM EDT
Baird analyst Brian Skorney lowered the price target on Biogen (NASDAQ: BIIB) to $250.00 (from $348.00) while maintaining a Neutral rating.
Skorney commented, "We are cutting our price target to $250 on the failure of aducanumab. The big question here is, where is the backstop? BIIB... More
